Oct 13 (Reuters) - ProMetic Life Sciences Inc PLI.TO :
* Prometic's pbi-4050 granted orphan drug designation for the treatment of
idiopathic pulmonary fibrosis in Europe
* Says Prometic is currently investigating the safety, tolerability and effects
of pbi-4050
* Expects to file ind with FDA during Q1 2016 for multi-center, double-blind,
placebo-controlled pivotal study with ipf patients
* Source text for Eikon ID:nMKWrrZfla
* Further company coverage PLI.TO